Table 2.
The changes in the phospholipid levels in the PFC and hippocampus following LPS and Pl injection
| Con | LPS | LPS + Pls | Pls | |
|---|---|---|---|---|
|
1) PFC |
|
|
|
|
| PlsEtn |
16.40 ± 0.59 |
13.41 ± 0.73* |
16.29 ± 0.53 |
17.81 ± 0.32 |
| PEtn |
21.92 ± 0.63 |
22.66 ± 0.65 |
22.48 ± 0.26 |
22.65 ± 0.22 |
| PlsCho |
0.20 ± 0.03 |
0.19 ± 0.03 |
0.21 ± 0.03 |
0.28 ± 0.04 |
| PCho |
44.04 ± 1.12 |
47.73 ± 1.04 |
43.73 ± 0.97 |
46.74 ± 0.85 |
| SM |
3.72 ± 0.20 |
3.13 ± 0.31 |
3.47 ± 0.24 |
3.31 ± 0.15 |
| PS |
11.88 ± 0.27 |
11.08 ± 0.30 |
12.03 ± 0.22 |
10.58 ± 0.56 |
| PI |
1.86 ± 0.12 |
1.80 ± 0.07 |
1.87 ± 0.21 |
1.64 ± 0.31 |
| PlsEtn/PEtn ratio |
0.75 ± 0.02 |
0.59 ± 0.03* |
0.73 ± 0.03 |
0.79 ± 0.01 |
|
2) Hippocampus |
|
|
|
|
| PlsEtn |
24.18 ± 0.64 |
20.29 ± 0.31* |
22.88 ± 0.45 |
22.68 ± 0.39 |
| PEtn |
20.38 ± 0.43 |
22.07 ± 0.62 |
20.21 ± 0.41 |
20.80 ± 0.57 |
| PlsCho |
0.49 ± 0.06 |
0.42 ± 0.04 |
0.45 ± 0.05 |
0.41 ± 0.03 |
| PCho |
36.90 ± 1.74 |
39.39 ± 0.38 |
37.64 ± 1.37 |
39.90 ± 1.04 |
| SM |
5.24 ± 0.67 |
5.36 ± 0.59 |
5.71 ± 0.64 |
4.13 ± 0.68 |
| PS |
11.73 ± 0.86 |
10.94 ± 0.25 |
11.71 ± 0.61 |
10.59 ± 0.34 |
| PI |
1.59 ± 0.10 |
1.63 ± 0.16 |
1.72 ± 0.06 |
1.48 ± 0.16 |
| PlsEtn/PEtn ratio | 1.19 ± 0.05 | 0.92 ± 0.03* | 1.14 ± 0.04 | 1.09 ± 0.05 |
The values are expressed as the mean ± SEM (n = 5) of the % level of the phospholipids, except for the last row. *, P <0.05 compared to the Con group (Steel test for multiple comparisons). Con, control; PCho, phosphatidyl choline; PEtn, phosphatidyl ethanolamine; PFS, prefrontal cortex; LPS, lipopolysaccharide; PI, phosphatidyl inositol; Pl, plasmalogen; PlsCho, choline plasmalogen; PlsEtn, ethanolamine plasmalogen; PS, phosphatidyl serine; SEM, standard error of the mean; SM, sphingomyelin.